Results 91 to 100 of about 289,772 (277)

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

open access: yesMolecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz   +15 more
wiley   +1 more source

Treatment of Barrett's Esophagus by radiofrequency ablation: a monocentrical study [PDF]

open access: yes, 2015
Background and aims: Barrett's esophagus (BE) is a frequent disease. Therapy by radiofrequency ablation (RFA) has been shown in literature to be an effective eradication therapy of BE, with a reasonable frequency of complications. The aim of our study is
GEIDER, N
core  

Class IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7‐mutated colorectal cancer

open access: yesMolecular Oncology, EarlyView.
HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto   +13 more
wiley   +1 more source

Barrett Esophagus: Quality of life and factors associated with illness perception. [PDF]

open access: yesUnited European Gastroenterol J, 2022
van der Ende-van Loon MCM   +9 more
europepmc   +1 more source

Crossing the threshold: a critical analysis of Levantine domestic architecture

open access: yes, 2010
Archaeologists studying ancient domestic architecture are often confronted with highly fragmentary architectural remains. This lack of data could lead to a focus on the visual comparison of floor plans as the most reliable and accessible source of ...
Brughmans, Tom
core  

Dual targeting of RET and SRC synergizes in RET fusion‐positive cancer cells

open access: yesMolecular Oncology, EarlyView.
Despite the strong activity of selective RET tyrosine kinase inhibitors (TKIs), resistance of RET fusion‐positive (RET+) lung cancer and thyroid cancer frequently occurs and is mainly driven by RET‐independent bypass mechanisms. Son et al. show that SRC TKIs significantly inhibit PAK and AKT survival signaling and enhance the efficacy of RET TKIs in ...
Juhyeon Son   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy